Exhibit 10.5


 


SECOND
AMENDMENT AGREEMENT 


TO


SUBSCRIPTION
AGREEMENT


 


THIS
SECOND AMENDMENT AGREEMENT TO SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the 16th of December, 2015 by
and between Moxian, Inc., a Nevada corporation (the “Company”), and Beijing Xinhua Huifeng Equity Investment Centre,
a limited partnership formed under the laws of People’s Republic of China (“Xinhua”). Each of the capitalized
terms not otherwise defined herein shall have the meanings ascribed to them in the Xinhua Subscription Agreement dated June 4,
2015 as defined below.


 


RECITALS:


 


WHEREAS,
on April 24, 2015, the Company entered into a subscription agreement (“Zhongtou Subscription Agreement”) with Zhongtou
Huifeng Investment Management (Beijing) Co. Ltd. (“Zhongtou”), whereby the Company agreed to sell 8,169,000 shares
of the Company’s common stock par value $.001 per share (“Common Stock”) at a per share price of $1.00 for gross
proceeds of $8,190,000 (approximately RMB50,000,000)(the “Purchase Price”) and to issue to Zhongtou for no additional
consideration a warrant (the “Warrant”) to purchase 32,000,000 shares (“Warrant Shares”) of Common Stock
at an exercise price of $2.00 per share, exercisable on or prior to July 31, 2015. On June 4, 2015, the Company and Zhongtou entered
into a Termination Agreement to terminate the Zhongtou Subscription Agreement as Zhongtou’s principals determined to make
the investment described in the Zhongtou Subscription Agreement through a different entity, Xinhua. Also on June 4, 2015, the
Company and Xinhua entered into a new Subscription Agreement (“Xinhua Subscription Agreement”) on substantially the
same terms as the Zhongtou Subscription Agreement (the “Transaction”), which is attached hereto as Exhibit A.
Pursuant to the Xinhua Subscription Agreement, Xinhua was to pay the Purchase Price to the Company on or before May 31, 2015 (the
“Closing Date”) and the Warrant was to be exercised by Xinhua on or before July 31, 2015 (the “Expiration Date”);
and


 


WHEREAS,
on August 13, 2015, Xinhua and the Company entered into an Amendment Agreement attached hereto as Exhibit B to extend
the Closing Date of the Transaction to September 30, 2015 and the expiration date of the Warrant to September 30, 2015 (such amendments,
the “First Amendment”); and


 


WHEREAS,
the parties hereto desire to further amend the Xinhua Subscription Agreement as set forth herein.


 


NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereby agree as follows:


 


Section
1.          Amendment of the Xinhua Subscription Agreement.


 


		(a)	The
                                         Closing Date of the Transaction shall be extended to December 31, 2015.
	 	 	 
		(b)	The
                                         Expiration Date of the Warrant shall be extended to December 31, 2015.



 






     

     


    

 


Section
2.          Miscellaneous.


 


(a)          Expenses. Each party shall bear its own costs and expenses, including legal fees, incurred or sustained in connection with
the preparation of this Agreement and related matters.


 


(b)         Waiver of Defaults. The Company hereby waives any and all defaults arising under the Xinhua Subscription Agreement and
the First Amendment, to release Xinhua from the obligations of such defaults and to waive any claims against Xinhua in connection
with such defaults or the transactions contemplated hereby,


 


(c)         Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and Xinhua.


 


(d)         Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be delivered as set forth in the Xinhua Subscription Agreement.


 


(e)         Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties


 


(f)          Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or “.pdf” signature page were an original thereof.


 


(g)         Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall
be determined in accordance with the provisions of the Xinhua Subscription Agreement.


 


(h)         Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.


 


(i)          Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall
not be deemed to limit or affect any of the provisions hereof.


 


(j)          Except as specifically contemplated by this Agreement, the Xinhua Subscription Agreement shall remain in full force and effect,
unaffected by this Agreement.






 






    	 	2	 



     


    

 





IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above.




 





	 	Moxian, Inc.
	 	 	 
	 	By:	 
	 	Name:	James
    Mengdong Tan
	 	Title:	CEO
	 	 	 
	 	Beijing
    Xinhua Huifeng Equity Investment Centre
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 







  



    	 	3	 



     


    







 


Exhibit
A


 


Subscription
Agreement


 






     

     


    



 


MOXIAN
CHINA, INC.


 


Investor Package


 


This Investor Package contains the documents
listed below in connection with an offering by Moxian China, Inc., a Nevada corporation (the “Company”), of
common stock, par value $.001 per share (“Common Stock”) for gross proceeds of up to $8,190,000 (or RMB 50,000,000)
or such other amount as may be determined by the Company’s board of directors.


 


Subscription Agreement; Schedules & Exhibits


Disclosure Schedules


Exhibit A Common Stock Purchase Warrant


 


Please deliver your investment amount via wire
or check payable to the Company’s account as attached herein as follows:


 


	Bank’s Name:	 
	Bank Address:	 
	Account #:	 
	Account Title:	 
	 	 




A signature page package containing segregated signature
pages for each of the following documents: (i) the Subscription Agreement together with the Exhibits and Schedules thereto (collectively,
the “Transaction Documents”) has been provided in a separate Adobe PDF file for your convenience.


 


Moxian China, Inc.     


 






    	 	A-1	 



     


    

 


Moxian
China, Inc.


 


SUBSCRIPTION AGREEMENT


 


Mr. James Mengdong Tan


CEO


Moxian China, Inc.


Room 2313-2315 , Block B, Zhongshen Garden


Caitian South Road, Futian District, Shenzhen


Guangdong Province, China 518101


 


This Subscription
Agreement (this “Agreement”) is dated as of _____________ by and between Moxian China, Inc., a Nevada corporation, and all
predecessors thereof (the “Company”), and the investor identified on the signature pages hereto
(the “Investor”). The undersigned investorhereby irrevocably subscribes for and agrees to purchase the
number of shares (the “Shares”) of the Company’s common stock, par value $.001 per share
(“Common Stock”), set forth on the signature page hereto from Moxian China, Inc., a Nevada corporation
(the “Company”) for the purchase price of $1.00 per share in connection with the Company’s offering
of $8,190,000 (or approximately RMB 50,000,000) (the “Investment Amount) in Common Stock together with a warrant
for no additional consideration (the “Offering”) in the form of Exhibit A hereto (the
“Warrant”), granting the Investor the right to purchase up to 32,000,000 shares of Common Stock of the
Company (Warrant Shares,” together with the Shares and Warrant Shares, referred to as the
“Securities”). The Warrants will have an initial exercise price equal to $2.00 per share and shall be
exercisable on or prior to July 31, 2015 (the “Expiration Date”).


 


This Subscription Agreement
together with the Exhibits and Schedules thereto constitutes the “Offering Documents.”


 


NOW THEREFORE,
in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:


 


1.
DEFINITIONS


 


1.1.	Definitions. In addition to the
terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated
in this Section 1.1:


 


“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or threatened in writing against or affecting the Company, any subsidiary or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency, regulatory or self-regulatory authority (federal, state, county,
local or foreign), stock market, stock exchange or trading facility.


 






    	 	A-2	 



     


    

 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.


 


“Business Day”
means any day except Saturday, Sunday and any day which is a federal legal holiday or a day on which banking institutions in the
State of New York are authorized or required by law or other governmental action to close.


 


“Closing”
means the closing of the purchase and sale of the Securities pursuant to Article 2.


 


“Closing Date”
means the Trading Day on which all of the conditions set forth in Sections 5.1 and 5.2 hereof are satisfied, or such other date
as the parties may agree.


 


“Commission”
means the Securities and Exchange Commission.


 


“Common Stock”
means the common stock of the Company, par value $0.001 per share, and any securities into which such common stock may hereafter
be reclassified or for which it may be exchanged as a class.


 


“Company”
has the meaning set forth in the preamble to this Agreement.


 


“Company Deliverables”
has the meaning set forth in Section 2.2(a).


 


“Disclosure Materials”
has the meaning set forth in Section 3.2(d).


 


“Exchange Act”
means the Securities Exchange Act of 1934, as amended.


 


“GAAP”
means U.S. generally accepted accounting principles.


 


“Investment Amount”
means shall have the definition set forth in the Recitals above.


 


“Investor Deliverables”
has the meaning set forth in Section 2.2(b).


 


“Lien”
means any lien, charge, encumbrance, security interest, pre-emptive right, right of first refusal, right of participation or any
other restrictions of any kind.


 


“Losses”
means any loss, liability, obligation, claim, contingency, damage, cost or expense, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys’ fees and costs of investigation related thereto.


 






    	 	A-3	 



     


    

 


“Material Adverse
Effect” means any of (i) a material and adverse effect on the legality, validity or enforceability of any Transaction
Documents, (ii) a material and adverse effect on the results of operations, assets, properties, prospects, business or condition
(financial or otherwise) of the Company, or (iii) an adverse impairment to the Company’s ability to perform on a timely basis
its obligations under any Transaction Documents; provided however, that none of the following shall be deemed in and of
themselves, either alone or in combination, to constitute, and none of the following shall be taken into account in determining
whether there has been or will be, a Material Adverse Effect: (i) any change, event, state of facts or development generally affecting
the general political, economic or business conditions of the United States; (ii) any change, event, state of facts or development
generally affecting the medical device industry; (iii) any change, event, state of facts or development arising from or relating
to compliance with the terms of this Agreement; (iv) acts of war (whether or not declared), the commencement, continuation or escalation
of a war, acts of armed hostility, sabotage or terrorism or other international or national calamity or any material worsening
of such conditions; (v) changes in laws or GAAP after date hereof or interpretation thereof; or (vi) any matter set forth
in the Transaction Documents or the Schedules or Exhibits thereto.


 


“New York Courts”
means the state and federal courts sitting in the City of New York, Borough of Manhattan.


 


“Per Share Purchase
Price” shall mean $1.00 per share.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition), whether commenced or threatened.


 


“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.


 


“Securities Act”
means the Securities Act of 1933, as amended.


 


“Securities”
shall have the meaning as set forth in the recital of this Agreement.


 


“Short Sales”
include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange
Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar arrangements
(including on a total return basis), and sales and other transactions through non-US broker dealers or foreign regulated brokers.


 


“Subsidiary”
of any Person means any “significant subsidiary” as defined in Rule 1-02(w) of the Regulation S-X promulgated by the
Commission under the Exchange Act of such Person.


 


“Trading Day”
means a day on which the principal Trading Market is open for trading.


 






    	 	A-4	 



     


    

 


“Trading Market”
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
OTCQB Marketplace of OTC Markets Group Inc., the NYSE MKT, the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global
Market or the Nasdaq Global Select Market (or any successors to any of the foregoing).


 


“Transaction Documents”
means this Agreement, the Warrant and any other documents or agreements executed in connection with the transactions contemplated
hereunder.


 


2. PURCHASE AND
SALE


 


	 	2.1.	Purchase and Sale; Closing. The closing of the purchase and sale of the Securities for the Investment Amount (the “Closing”)
shall take place as soon as practicable following the satisfaction of the conditions to the Closing set forth herein (or such
later date as is mutually agreed to by the Company and the Investor) (the date of any such Closing is hereinafter referred to
as a “Closing Date”). The Closing shall take place at the offices of the Company at Room 2313-2315, Block B,
Zhongshen Garden, Caitian South Road, Futian District, Shenzhen, Guangdong Province, China 518101 on the Closing Date or at such
other location or time as the parties may agree.




 


	 	2.2.	Closing Deliveries.




 


(a)	The Company shall deliver or
cause to be delivered to the Investor the following (the “Company Deliverables”):


 


(i)	this Agreement,
duly executed by the Company; and


 


(ii)	the Warrant
duly executed by the Company.


 


(iii)	Executed
resolution by the Board of Directors authorizing the Company to offer its common shares for subscription by the Investor at the
price of $1.00 per share and granting the Investor a warrant at no additional consideration to purchase up to 32,000,000 common
shares at $2.00 per shares.


 


(b)	At the Closing, Investor shall
deliver or cause to be delivered the following to the Company (collectively, the “Investor Deliverables”):


 


(i)	this Agreement,
duly executed by the Investor;


 


(ii)	Wire proof
of the Investment Amount to the designated account as specified under this Agreement before 30th May 2015. The Company
agrees and acknowledges that the investment funds, once they are wired to the Company, or one of its subsidiaries, will be valid
consideration for the subscribed securities.


 






    	 	A-5	 



     


    

 


WIRING INSTRUCTIONS


 





	Bank’s Name:	China Merchants Bank, Anlian
        Branch




	Bank Address:	1st
        Floor, Area B Anlian Building, 4081-1 Jintian Rd, Futian District, Shenzhen




	Account #:	7559 2020 9810 803




	Account Title:	Moxian Technologies (Shenzhen)
        Co, Ltd




	 	魔线科技(深圳)有限公司


 














3. REPRESENTATIONS
AND WARRANTIES


 


3.1	Representations and Warranties of the
Company. Except as set forth in the Disclosure Schedules attached hereto (the “Disclosure Schedules”), the Company
hereby represents and warrants to the Investor the following:


 


(a)	Organization
and Standing. The Company is duly incorporated and validly existing under the laws of the State of Nevada, and has all requisite
corporate power and authority to own or lease its properties and assets and to conduct its business as it is presently being conducted.
The Company does not own any equity interest, directly or indirectly, in any other Person or business enterprise. The Company is
in good standing in the State of Nevada and is qualified to do business and is in good standing in each jurisdiction in which the
failure to so qualify could reasonably be expected to have a Material Adverse Effect upon its assets, properties, financial condition,
results of operations or business. Except as provided in Schedule 3.1(a) attached herein, the Company does not own or control
any subsidiaries as of the date of this Agreement.


 


(b)	Authorization; Enforcement. The
Company has full corporate power and authority to execute and deliver this Agreement, and any documents and instruments related
to or contemplated by each of the Transaction Documents to which it is or will be a party and to perform its obligations hereunder
and thereunder, and to consummate the transactions contemplated hereby and thereby. The execution and delivery by the Company of
each of the Transaction Documents and the performance by the Company of its obligations thereunder, have been duly and validly
authorized by the Board of Directors, no other corporate action on the part of the Company or its stockholders being necessary.
Each of the Transaction Documents has been or will be duly and validly executed and delivered by the Company, and constitutes,
or will constitute a legal, valid and binding obligation of the Company enforceable against the Company in accordance with their
respective terms except as enforceability may be limited by bankruptcy, insolvency and other laws of general application affecting
the enforcement of creditors’ rights and except that any granting of equitable relief is in the discretion of the court.


 






    	 	A-6	 



     


    

 


(c)	No Conflicts.
The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated thereby do not and will not (i) conflict with or violate any provision of the Company’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument or other understanding to which the Company is a party or by which any property or asset of the Company is
bound or affected, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company is subject (including United States federal and state securities laws
and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses
(ii) and (iii), such as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse
Effect.


 


(d)	Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization, approval or order of, give any
notice to, or make any filing or registration with, any federal, provincial, state, local or other governmental authority or any
other Person in connection with the execution, delivery and performance by the Company to the extent a party thereto of the Transaction
Documents, other than (i) filings required by state securities laws, (ii) the filing of a Notice of Sale of Securities on Form
D with the Commission under Regulation D of the Securities Act, (iii) filings, consents and approvals required by the rules and
regulations of the applicable Trading Market and (iv) those that have been made or obtained prior to the date of this Agreement.


 


(e)	Issuance
of the Securities. The Securities have been duly authorized and, when issued and paid for in accordance with the Transaction Documents,
will be duly and validly issued, fully paid and non-assessable, free and clear of any and all Liens. For the issuance of the Securities,
the Company has reserved from its duly authorized capital stock the number shares of Common Stock representing the Securities that
are issuable pursuant to this Agreement. In addition, attached in Schedule 3(e) is the Company’s
legal counsel opinion for that the issuance of Securities complies with the relevant legal rules and regulations and in reliance
to the applicable federal and state law.


 


(f)	Capitalization.
The number of shares of all authorized, issued and outstanding capital stock of the Company are specified in Schedule 3.1(f).
No securities of the Company are entitled to preemptive or similar rights, and no Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.
Except as set forth on Schedule 3.1(f), there are no outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exchangeable for,
or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company is or may become bound to issue additional shares of Common Stock, or securities or rights
convertible or exchangeable into shares of Common Stock. The issue and sale of the Securities hereunder will not, immediately or
with the passage of time, obligate the Company to issue shares of Common Stock or other securities to any Person (other than the
Investors) and will not result in a right of any holder of the Company’s securities to adjust the exercise, conversion, exchange
or reset price under such securities.


 






    	 	A-7	 



     


    

 


(g) Litigation. There is
no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents
or the Securities or (ii) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect.


 


The Investor hereby acknowledges
and agrees that the Company does not make and has not made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in this Section 3.1.


 


3.2	Representations and Warranties of the
Investors. The Investor hereby, for itself and for no other Investor, represents and warrants to the Company as follows:


 


(a)	Organization;
Authority. The Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of
its organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions
contemplated by the applicable Transaction Documents and otherwise to carry out its obligations thereunder. The execution, delivery
and performance by the Investor of the transactions contemplated by this Agreement has been duly authorized by all necessary corporate
or, if the Investor is not a corporation, such partnership, limited liability company or other applicable like action, on the part
of such Investor. Each of this Agreement and other Transaction Documents has been duly executed by the Investor, and when delivered
by such Investor in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Investor,
enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general application.


 


(b)	Investment
Intent. Such Investor is acquiring the Securities as principal for its own account of the limited partnership of which the Investor
is the general partner and manager and for investment purposes only and not with a view to or for distributing or reselling such
Securities or any part thereof, without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose
of all or any part of such Securities in compliance with applicable federal and state securities laws. Subject to the immediately
preceding sentence, nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities
for any period of time. Such Investor is acquiring the Securities hereunder in the ordinary course of its business. Such Investor
does not have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities.


 






    	 	A-8	 



     


    

 


(c)	Investor
Status.


 


(i)	The Investor
agrees and acknowledges that it was not, a “U.S. Person” (as defined below) at the time the Investor was offered the
Securities and as of the date hereof:


 


(A) 	any natural person resident
in the United States;


 


(B) 	any partnership or corporation
organized or incorporated under the laws of the United States;


 


(C) 	any estate of which any executor
or administrator is a U.S. person;


 


(D) 	any trust of which any trustee
is a U.S. person;


 


(E) 	any agency or branch of a foreign
entity located in the United States;


 


(F) 	any non-discretionary account
or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person;


 


(G) 	any discretionary account or
similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual)
resident of the United States; and


 


(H) 	any partnership or corporation
if (i) organized or incorporated under the laws of any foreign jurisdiction and (ii) formed by a U.S. person principally for the
purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned,
by accredited Investors (as defined in Rule 501(a) of Regulation D promulgated under the Securities Act) who are not natural persons,
estates or trusts.


 


“United States”
or “U.S.” means the United States of America, its territories and possessions, any State of the United States,
and the District of Columbia.


 


(ii)	The Investor
understands that no action has been or will be taken in any jurisdiction by the Company that would permit a public offering of
the Securities in any country or jurisdiction where action for that purpose is required.


 


(iii)	The Investor
(i) as of the execution date of this Agreement is not located within the United States, and (ii) is not purchasing the Securities
for the account or benefit of any U.S. Person, except in accordance with one or more available exemptions from the registration
requirements of the Securities Act or in a transaction not subject thereto.


 


(iv)	The Investor
will not resell the Securitiess except in accordance with the provisions of Regulation S (Rule 901 through 905 and Preliminary
Notes thereto), pursuant to a registration statement under the Securities Act, or pursuant to an available exemption from registration;
and agrees not to engage in hedging transactions with regard to such securities unless in compliance with the Securities Act.


 






    	 	A-9	 



     


    

 


(v)	The Investor
will not engage in hedging transactions with regard to shares of the Company prior to the expiration of the distribution compliance
period specified in Category 2 or 3 (paragraph (b)(2) or (b)(3)) in Rule 903 of Regulation S, as applicable, unless in compliance
with the Securities Act; and as applicable, shall include statements to the effect that the securities have not been registered
under the Securities Act and may not be offered or sold in the United States or to U.S. persons (other than distributors) unless
the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act
is available.


 


(vi)	No form
of “directed selling efforts” (as defined in Rule 902 of Regulation S under the Securities Act), general solicitation
or general advertising in violation of the Securities Act has been or will be used nor will any offers by means of any directed
selling efforts in the United States be made by the Investor or any of their representatives in connection with the offer and sale
of the Securities.


 


(d)	Access to
Information. The Investor acknowledges that it has reviewed the disclosure materials provided by the Company and has been afforded
(i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company
concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities;
(ii) access to information about the Company and its respective financial condition, results of operations, business, properties,
management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional
information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf
of such Investor or its representatives or counsel shall modify, amend or affect such Investor’s right to rely on the truth,
accuracy and completeness of the Disclosure Materials and the Company’s representations and warranties contained in the Transaction
Documents.


 


(e)	The Investor
understands that the offering of the Securities has not been registered under the Securities Act, in reliance on an exemption for
private offerings provided pursuant to Section 4(2) of the Securities Act and that, as a result, the Securities will be “restricted
securities” as that term is defined in Rule 144 under the Securities Act. UNTIL ONE YEAR AFTER THE COMPANY FILES
“Form 10” information with the commission and the other provisins of rule 144 are satisfied, RULE 144 WILL BE
UNAVAILABLE AND THE SECURITIES MAY NOT BE SOLD OTHER THAN IN A PRIVATE TRANSACTION. Once Rule 144 is available, the Securities
must be held for the time period required by Rule 144 (or indefinitely if the Investor is deemed an “affiliate” within
the meaning of such rule) unless the Securities is subsequently registered under the Securities Act and qualified under any other
applicable securities law or exemptions from such registration and qualification are available. The Investor understands that the
Company is under no obligation to register the Securities under the Securities Act or to register or qualify the Securities under
any other applicable securities law, or to comply with any other exemption under the Securities Act or any other securities law,
and that the Investor has no right to require such registration. The Investor understands that the Company has no present intention
to register any of the Securities for re-sale by Investor. The Investor further understands that the Offering of the Securities
has not been qualified or registered under any foreign or state securities laws in reliance upon the representations made and information
furnished by the Investor herein and any other documents delivered by the Investor in connection with this subscription; that the
Offering has not been reviewed by the Commission or by any foreign or state securities authorities; that the Investor’s rights
to transfer the Securities will be restricted, which includes restrictions against transfers unless the transfer is not in violation
of the Securities Act and applicable state securities laws (including investor suitability standards); and that the Company may
in its sole discretion require the Investor to provide at Investor’s own expense an opinion of its counsel to the effect
that any proposed transfer is not in violation of the Securities Act or any state securities laws.


 






    	 	A-10	 



     


    

 


(f)	Independent
Investment Decision. The Investor has independently evaluated the merits of its decision to purchase the Securities pursuant to
the Transaction Documents, and such Investor confirms that it has not relied on the advice of any other Investor’s business
and/or legal counsel in making such decision. The Investor has not relied on the business or legal advice of the Company or any
of its agents, counsel or Affiliates in making its investment decision hereunder, and confirms that none of such Persons has made
any representations or warranties to such Investor in connection with the transactions contemplated by the Transaction Documents,
other than the representations made by the Company.


 


(g)	Trading
Activities. Neither the Investor nor its Affiliates has an open short position in the Company’s Common Stock, and the Investor
agrees that it shall not, and it will cause its Affiliates not to, engage in any Short Sales of or hedging transactions with respect
to the Company’s Common Stock.


 


The Company acknowledges
and agrees that no Investor has made or makes any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in this Section 3.2.


 


4. OTHER AGREEMENTS
OF THE PARTIES


 


4.1	Securities may only be disposed
of in compliance with U.S. state and federal securities laws. In connection with any transfer of the Securities other than pursuant
to an effective registration statement, to the Company, to an Affiliate of an Investor or in connection with a pledge as contemplated
in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Securities under the Securities Act.


 


(a)	Certificates
evidencing the Securities will contain the following legend:


 


THESE SECURITIES HAVE NOT BEEN REGISTERED
WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. NOTWITHSTANDING THE FOREGOING, THESE SECURITIES MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.


 






    	 	A-11	 



     


    

 


4.2	Integration. The Company shall not,
and shall use its best efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy
or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with
the offer or sale of the Securities in a manner that would require the registration under the
Securities Act of the sale of the Securities to the Investors, or that would be integrated
with the offer or sale of the Securities for purposes of the rules and regulations of any Trading
Market in a manner that would require stockholder approval of the sale of the Securities to
the Investors.


 


4.3	Use of Proceeds. The Company will use
the net proceeds from the sale of the Securities hereunder for working capital purposes and such other purposes as set forth on
Schedule 4.6 hereto.


 


4.4	Make Good Provision. If and only if the
Investor exercises no less than16,000,000 of the Warrant and purchases shares of Common Stock pursuant to such exercise prior to
the Expiration Date, the Investor shall be entitled to the following rights:


 


(a)	In the event
that the Company does not contract with 25,000 new Paying Merchants (the “Make
Good Condition”) between May 30, 2015 and September 30, 2016
(“Measurement Date”),
the Company shall issue and deliver to the Investor, without additional consideration, a number of shares of Common Stock in addition
to the Shares, which is calculated as the following: the total number of Warrant Shares issued upon exercise of the Warrants by
the Investor, multiplied by 50% (the “Make Good Shares”).


 






    	 	A-12	 



     


    

 


(b)	For the
purpose of determining the satisfaction of Make Good Condition on the Measurement Date, the Company shall produce and provide to
the Investor a list of paying merchants, generated from its online platform no later than 15 days after the Measurement Date (the
“Make Good Notice”). If the Company satisfies the Make Good Condition on the Measurement Date, the Company shall
so state in the Make Good Notice and it shall have no further obligation to issue Make Good Shares to the Investor. If the Company
fails to satisfy the Make Good Condition, the Company shall so state in the Make Good Notice and set forth the number of Make Good
Shares to be issued to the Investor. The Company shall issue and deliver to the Investor the Make Good Shares no later than thirty
(30) days after the Measurement Date.


 


4.5
Board Representation. As long as the Investor completes the subscription of US$8,190,000 subscription under this Agreement, the
Investor shall have the right to nominate up to one memberto the Board of Directors (the ”Investor
Nominees”). The Investor may notify the Company of the
Investor Nominees to be elected or appointed as directors of the Company immediately after the Closing and the Board of Directors
of the Company shall take such steps as may be necessary to add the Investor Nominees to the Company’s
Board of Directors. As long as the Investor subscribes no less than 16,000,000 warrant on this Agreement, the Investor will have
the right to appoint one additional member to the Board of Directors.


 


4.6
Accounts Representation. As long as the Investor completes the subscription of US$8,190,000 subscription under this Agreement,
the Investor shall have the right to nominate up to one member to the Company accounting department (the “Account
Nominees”). The Investor shall notify the Company of
the Account Nominees to be elected or appointed to the Company immediately after the Closing and the Company shall take such steps
as may be necessary to employ the Account Nominees to the Company.


 


4.7
Moxian Version 2.0. The Company hereby covenants and agrees to use its reasonable best efforts to release the Moxian Version 2.0
Beta App by June 30, 2015 and a full working version of Moxian 2.0 App as described under Schedule 1.7 by September 30, 2015.
If the Company fails to deliver Moxian Version 2.0 by September 30, 2015, the Company shall issue to the Investor 4,000,000 shares
at no cost.(such amount may be adjusted as a result of a stock split or a similar event).


 


4.8
Uplisting. The Company hereby covenants and agrees to use its reasonable best efforts to list its Common Stock on a national stock
exchange in the U.S., including but not limited to, the NYSE MKT, the New York Stock Exchange, the Nasdaq Capital Market, the
Nasdaq Global Market or the Nasdaq Global Select Market (or any successors to any of the foregoing)(’Exchange’),
prior to June 30, 2017. If the Company fails to uplift to an Exchange by June 30, 2017, the Company shall issue to the Investor
4,000,000 shares at no cost.(such amount may be adjusted as a result of a stock split or a similar event).


 






    	 	A-13	 



     


    

 


4.9
Further Assurances. The Company shall use its reasonable best efforts to satisfy all of the closing conditions under Section 5.1,
and will not take any action which could frustrate or delay the satisfaction of such conditions. In addition, either prior to
or following the Closing, the Company signatory hereto will perform, or cause to be done and performed, all such further acts
and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party
may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby. The Company will also inform its legal counsel to provide a confirmation of the Investors
full payment of the subscribed shares upon receipt of funds from the Investor.


 


4.10
Covenants of the Company. The Company hereby agrees to make reasonable and practicable efforts to assist the Investor
with the following:


 


(a) In the event the Investoris
dissolved for reasons other than bankruptcy, upon written request from the Investor, the Company shall use its commercially reasonable
efforts to assist the Assignee by providing necessary documentation for the assignment and the transfer of the Shares and Warrant
Shares, if any,to the partners of the Investorin proportion their respectiveownership interest in the Investor; provided that such
transfer and assignment complies with all applicable federal and state securities laws and that such transferees agree in writing
with the Company to be bound, with respect to the transferred Shares and Warrant Shares, if any, by the provisions of the Subscription
Agreement that apply to the “Investor.” 


 


(b) As an accommodation
to the Investor, the Company hereby agrees that upon written request by the Investor, the Company shall use its commercially reasonable
efforts to provide the Investorwith a list of recommended United States broker-dealers that the Company reasonably believes to
be suitable to assist Chinese entities or individuals in executing stock sales in the U.S. The Company shall not indicate to
the Investorits preference to any of the recommended broker-dealers and the Investorshall have the right to engage other broker-dealers
that are not on the recommended list.The Company will not provide any advice or direction with respect to the sale of stock nor
the timing of such sales. 


 


(c) The Company hereby
agrees that it shall use its commercially reasonable efforts to assist the Investor to provide written draft instructions to provide
to the chosen broker-dealer of the Investor to wire the funds derived from the execution of stock sales in U.S. to their home country
bank account.


 


5.
CONDITIONS PRECEDENT TO CLOSING


 


5.1	Conditions Precedent to the Obligations
of the Investors to Purchase Securities. The obligation of the Investor to acquire Securities at the Closing is subject to
the satisfaction or waiver by the Investor, at or before the Closing, of each of the following conditions:


 


(a)	Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material respects
as of the date when made and as of the Closing as though made on and as of such date;


 


(b)	Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing;


 






    	 	A-14	 



     


    

 


(c)	No Injunction.
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents;


 


(d)	Adverse
Changes. Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably could
have or result in a Material Adverse Effect or a material adverse change with respect to the Company; and


 


(e)	Company
Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).


 


5.2	Conditions Precedent to the Obligations
of the Company to Sell Securities. The obligation of the Company to sell Securities at the Closing is subject to the satisfaction
or waiver by the Company, at or before the Closing, of each of the following conditions:


 


(a)	Representations
and Warranties. The representations and warranties of the Investor contained herein shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though made on and as of such date;


 


(b)	Performance.
The Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by such Investor at or prior to the Closing;


 


(c)	No Injunction.
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents; and


 


(d)	Investors
Deliverables. The Investor shall have delivered the Investor Deliverables in accordance with Section 2.2(b).


 


6.
MISCELLANEOUS


 


6.1	Entire Agreement. The Transaction Documents,
together with the Exhibits and Schedules thereto, contain the entire understanding of the parties with respect to the subject matter
hereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.


 






    	 	A-15	 



     


    

 


6.2	Notices. Any and all notices or other
communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective
on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile (provided the sender
receives a machine-generated confirmation of successful transmission) at the facsimile number specified in this Section prior to
6:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in this Section on a day that is not a Trading Day or later than 6:30
p.m. (New York City time) on any Trading Day, or (c) upon actual receipt by the party to whom such notice is required to be given,
if sent by any means other than facsimile transmission, or (d) by registered mail and or by private courier with the date of confirmation
of receipt to the office desk.


 


6.3	The address for such notices and communications
shall be as follows:


 


	 	If to the Company:	 Moxian China, Inc.
	 	 	Room 2313-2315 , Block B, Zhongshen
Garden
	 	 	Caitian South Road, Futian
District, Shenzhen
	 	 	Guangdong Province, China
518101
	 	 	Attn: Mr. James Mengdong Tan



 


	 	With a copy to:	Ofsink, LLC
	 	 	230 Park Ave, Suite 851
	 	 	New York, NY 10169
	 	 	Facsimile: 646-224-9844
	 	 	Attn.: Darren Ofsink, Esq.
	 	 	 
	 	If to an Investor:	To the
address set forth under such Investor’s name on the signature pages hereof;



 


or such other address as may be designated
in writing hereafter, in the same manner, by such Person.


 


6.4	Amendments; Waivers; No Additional Consideration.
No provision of this Agreement may be waived or amended except in a written instrument signed by the Company and the Investor.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.
No consideration shall be offered or paid to the Investor to amend or consent to a waiver or modification of any provision of any
Transaction Document unless the same consideration is also offered to all Investors who then hold Securities.


 


6.5	Construction. The headings herein are
for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent,
and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly
by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement or any of the Transaction Documents.


 






    	 	A-16	 



     


    

 


6.6	Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign
this Agreement or any rights or obligations hereunder without the prior written consent of the Investors. The Investor may assign
any or all of its rights under this Agreement to any Person to whom such Investor assigns or transfers any Securities, provided
such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions hereof that apply
to the “Investors.” Notwithstanding anything to the contrary herein, for the avoidance of doubt, each Investor may
freely transfer any Securities to any Person (including its Affiliates or any investment fund sponsored or advised by such Investor)
without the consent of any of the Company or any other Investor.


 


6.7	No Third-Party Beneficiaries. This Agreement
is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.


 


6.8	Governing Law. This Agreement shall
be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation
and performance of this Agreement shall be governed by, the internal laws of the State of New York, without giving effect to any
choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause
the application of the laws of any jurisdictions other than the State of New York. Each of the parties hereto hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in New York, New York for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action
or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or
rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified
to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not
affect the validity or enforceability of any other provision of this Agreement.


 


6.9	Survival. The representations, warranties,
agreements and covenants contained herein shall survive the Closing and the delivery of the Securities.


 


6.10	Execution. This Agreement may be executed
in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not
sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile signature page were an original thereof.


 






    	 	A-17	 



     


    

 


6.11	Severability. If any provision of this
Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable
provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.


 


6.12.1
Replacement of Securities. If any certificate or instrument evidencing any Securities is
mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if
requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs associated with the issuance of such replacementSecurities. If a
replacement certificate or instrument evidencing any Securities is requested due to a
mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to
any issuance of a replacement. Language and Copies of Agreement. This Agreement shall be executed in English and Chinese in
duplicate, and in case of any conflict the English version shall prevail. Each of the original English and Chinese versions
of this Agreement shall be executed in 2 duplicate copies. Each party shall hold two originals of each version.


 


[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK

SIGNATURE PAGES FOLLOW]


 






    	 	A-18	 



     


    

 


IN WITNESS WHEREOF, the
parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of date
first written above.


 





	 	Moxian China, Inc.
	 	 
	 	By:	 
	 	 	Name: James Mengdong Tan
	 	 	Title:   Interim Chief Executive Officer




 






    	 	A-19	 



     


    

 


IN WITNESS WHEREOF, the
parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as the date
set forth above.


 





	 	INVESTOR
	 	 	 
	 	BEIJING XINHUA HUIFENG EQUITY INVESTMENT CENTRE (LIMITED PARTNERSHIP)
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:




 





	 	Investment
    Amount:  $_____________
	 	Total
    Number of Subscribed Shares: ____________________
	 	 
	 	If
    a U.S. Person, Tax ID or SSN No.:___________
	 	If
    not a U.S. Person, country of incorporation or citizenship: _____________________
	 	 
	 	ADDRESS
    FOR NOTICE
	 	Beijing
    City, Haiding Qu, Zhongguan Village
	 	66NorthRoad,
    Block 1, Level 2, Commercial Centre 5-079
	 	 
	 	Attention:  He
    Weisu
	 	Tel:
    +86 139-0136-8633
	 	Email:  weisuhe@163.com
	 	 
	 	MAILING
    ADDRESS
	 	(if
    different from above)
	 	 
	 	 
	 	 
	 	 
	 	Attention:  _____________________________
	 	Tel:
	 	Email:  _________________________________







 






    	 	A-20	 



     


    

 


DISCLOSURE SCHEDULES


Schedule 3.1(a)


 


Subsidiaries


 


As of the date of this Agreement herein, the Company has the following
subsidiaries:


 


	Name	 	Jurisdiction	 	
        Equity Owners and
        Percentage

        of Equity Securities Held

	 	 	 	 	 
	Moxian CN Group Limited	 	Samoa	 	100% owned by Moxian China, Inc.
	 	 	 	 	 
	Moxian Group Limited	 	British Virgin Islands	 	100% owned by the Moxian CN Group Limited
	 	 	 	 	 
	Moxian (Hong Kong) Limited	 	Hong Kong	 	100% owned by Moxian Group Limited
	 	 	 	 	 
	Moxian Technologies (Shenzhen) Co., Ltd.	 	PRC	 	100% owned by Moxian (Hong Kong) Limited
	 	 	 	 	 
	Moxian Malaysia SDN BHD	 	Malaysia	 	100% owned by Moxian (Hong Kong) Limited


 






    	 	A-21	 



     


    

 


Schedule 3.1(f)


 


Capitalization


 


As of the date of this Agreement, the Company is authorized to issue
a total of 500,000,000 shares of Common Stock, with 198,300,000 shares issued and outstanding and the Company is authorized to
issue 100,000,000 shares of preferred stock, par value $0.001 per share with no share issued or outstanding.


 


There are no warrants or options or any obligation to issue the
Company’s securities issued and outstanding as of the date of this Agreement.


 






    	 	A-22	 



     


    

 


Schedule 4.6


 


Use of Proceeds


 


We intend to use the estimated net proceeds of the Offering for
working capital.


 






    	 	A-23	 



     


    

 







EXHIBIT
A


 


For
U.S. Investors


 


these
securities have not been registered with the united states securities and exchange commission or the securities commission of
any state pursuant to an exemption from registration under regulation d promulgated under the securities act of 1933, as amended
(the “act”). this warrant shall not constitute an offer to sell nor a solicitation of an offer to buy the securities
in any jurisdiction in which such offer or solicitation would be unlawful. the securities are “restricted” and may
not be resold or transferred except as permitted under the act pursuant to registration or exemption therefrom.


 


For
Non-U.S. Investors:


 


THESE
SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S) PURSUANT TO
REGULATION S PROMULGATED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). ACCORDINGLY,
NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT, OR ANY U.S. STATE SECURITIES LAWS, AND,
UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT, AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING
TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE SECURITIES ACT.


 


	COMMON
STOCK PURCHASE WARRANT 


 


To
Purchase Shares of $0.001 Par Value Common Stock (“Common Stock”) of


 


No.
[W-__]	


 


MOXIAN
CHINA, INC.


 


THIS
CERTIFIES that, for value received, BEIJING XINHUA HUIFENG EQUITY INVESTMENT CENTRE (LIMITED PARTNERSHIP) (the “Purchaser”
or “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on
or after the date hereof and on or prior to 8:00 p.m. New York City Time on July 31, 2015 (the “Termination Date”),
but not thereafter, to subscribe for and purchase from Moxian China, Inc., a Nevada corporation (the “Company”)
up to 32,000,000 shares of the Company’s common stock (“Warrant Shares”) at an initial exercise price
of $2.00 per share (as adjusted from time to time pursuant to the terms hereof, the “Exercise Price”).


 


The
Exercise Price and the number of shares for which the Warrant is exercisable shall be subject to adjustment as provided herein.
This Warrant is being issued in connection with the Subscription Agreement dated _________ (the “Subscription Agreement”),
entered into between the Company and accredited investors in connection with the Company’s offering by the Company of its
Common Stock (the “Common Stock,” and such offering, the “Offering”).


 






    	 	A-24	 



     


    

 


Capitalized
terms used herein and not otherwise defined shall have the meaning ascribed to them in the Subscription Agreement.


 


		1.	Title
                                         of Warrant. Prior to the expiration hereof and subject to compliance with applicable
                                         laws, this Warrant and all rights hereunder are transferable, in whole or in part, at
                                         the office or agency of the Company by the Holder hereof in person or by duly authorized
                                         attorney, upon surrender of this Warrant together with (a) the Assignment Form
                                         annexed hereto properly endorsed, and (b) any other documentation reasonably necessary
                                         to satisfy the Company that such transfer is in compliance with all applicable securities
                                         laws. The term “Holder” shall refer to the Purchaser or any subsequent
                                         transferee of this Warrant.



 


		2.	Authorization
                                         of Shares. The Company covenants that all shares of Common Stock which may be
                                         issued upon the exercise of rights represented by this Warrant will, upon exercise of
                                         the rights represented by this Warrant and payment of the Exercise Price as set forth
                                         herein, be duly authorized, validly issued, fully paid and non-assessable and free from
                                         all taxes, liens and charges in respect of the issue thereof (other than taxes in respect
                                         of any transfer occurring contemporaneously with such issue or otherwise specified herein).



 


		3.	Exercise
                                         of Warrant.



 


		a.	The
                                         Holder may exercise this Warrant, in whole or in part, at any time and from time to time
                                         by delivering (which may be by facsimile) to the offices of the Company or any transfer
                                         agent for the Common Stock this Warrant, together with a Notice of Exercise in
                                         the form annexed hereto specifying the number of Warrant Shares with respect to which
                                         this Warrant is being exercised, together with payment in cash to the Company of the
                                         Exercise Price therefore.



 


		b.	In
                                         the event that the Warrant is not exercised in full, the number of Warrant Shares shall
                                         be reduced by the number of such Warrant Shares for which this Warrant is exercised and/or
                                         surrendered, and the Company, if requested by Holder and at its expense, shall within
                                         five (5) Trading Days (as defined below) issue and deliver to the Holder a new Warrant
                                         of like tenor in the name of the Holder or as the Holder (upon payment by Holder of any
                                         applicable transfer taxes) may request, reflecting such adjusted Warrant Shares. Notwithstanding
                                         anything to the contrary set forth herein, upon exercise of any portion of this Warrant
                                         in accordance with the terms hereof, the Holder shall not be required to physically surrender
                                         this Warrant to the Company unless such Holder is purchasing the full amount of Warrant
                                         Shares represented by this Warrant. The Holder and the Company shall maintain records
                                         showing the number of Warrant Shares so purchased hereunder and the dates of such purchases
                                         or shall use such other method, reasonably satisfactory to the Holder and the Company,
                                         so as not to require physical surrender of this Warrant upon each such exercise. The
                                         Holder and any assignee, by acceptance of this Warrant or a new Warrant, acknowledge
                                         and agree that, by reason of the provisions of this Section, following exercise of any
                                         portion of this Warrant, the number of Warrant Shares which may be purchased upon exercise
                                         of this Warrant may be less than the number of Warrant Shares set forth on the face hereof.
                                         Certificates for shares of Common Stock purchased hereunder shall be delivered to the
                                         Holder hereof within ten (10) Trading Days after the date on which this Warrant shall
                                         have been exercised as aforesaid. The Holder may withdraw its Notice of Exercise at any
                                         time if the Company fails to timely deliver the relevant certificates to the Holder as
                                         provided in this Agreement. A Notice of Exercise shall be deemed sent on the date of
                                         delivery if delivered before 8:00 p.m. New York Time on such date, or the day following
                                         such date if delivered after 8:00 p.m. New York Time; provided that the Company is only
                                         obligated to deliver Warrant Shares against delivery of the Exercise Price from the holder
                                         hereof and, if the Holder is purchasing the full amount of Warrant Shares represented
                                         by this Warrant, surrender of this Warrant (or appropriate affidavit and/or indemnity
                                         in lieu thereof).



 






    	 	A-25	 



     


    

 


The
Company’s obligations to issue and deliver Warrant Shares upon an exercise in accordance with Section 3 above are absolute
and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect
to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim,
recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to
the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance
which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing
herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.


 


		4.	No
                                         Fractional Shares or Scrip. No fractional shares or scrip representing fractional
                                         shares shall be issued upon the exercise of this Warrant. In lieu of issuance of a fractional
                                         share upon any exercise hereunder, the Company will either round up to nearest whole
                                         number of shares or pay the cash value of that fractional share, which cash value shall
                                         be calculated on the basis of the average closing price of the Common Stock during the
                                         five (5) Trading Days immediately preceding the date of exercise.
	 	 	 
		5.	Charges,
                                         Taxes and Expenses. Issuance of certificates for shares of Common Stock upon
                                         the exercise of this Warrant shall be made without charge to the Holder hereof for any
                                         issue or transfer tax or other incidental expense in respect of the issuance of such
                                         certificate, all of which taxes and expenses shall be paid by the Company, and such certificates
                                         shall be issued in the name of the Holder of this Warrant or in such name or names as
                                         may be directed by the Holder of this Warrant; provided, however, that in the event certificates
                                         for shares of Common Stock are to be issued in a name other than the name of the Holder
                                         of this Warrant, this Warrant when surrendered for exercise shall be accompanied by the
                                         Assignment Form attached hereto duly executed by the Holder hereof; and provided further,
                                         that the Company shall not be required to pay any tax or taxes which may be payable in
                                         respect of any transfer involved in the issuance of any Warrant certificates or any certificates
                                         for the Warrant Shares other than the issuance of a Warrant Certificate to the Holder
                                         in connection with the Holder’s surrender of a Warrant Certificate upon the exercise
                                         of all or less than all of the Warrants evidenced thereby.



 






    	 	A-26	 



     


    

 


		6.	Closing
                                         of Books. The Company will at no time close its shareholder books or records
                                         in any manner which interferes with the timely exercise of this Warrant.
	 	 	 
		7.	No
                                         Rights as Shareholder until Exercise. Subject to Section 13 of this Warrant and
                                         the provisions of any other written agreement between the Company and the Purchaser,
                                         the Purchaser shall not be entitled to vote or receive dividends or be deemed the holder
                                         of Warrant Shares or any other securities of the Company that may at any time be issuable
                                         on the exercise hereof for any purpose, nor shall anything contained herein be construed
                                         to confer upon the Purchaser, as such, any of the rights of a stockholder of the Company
                                         or any right to vote for the election of directors or upon any matter submitted to stockholders
                                         at any meeting thereof, or to give or withhold consent to any corporate action (whether
                                         upon any recapitalization, issuance of stock, reclassification of stock, change of par
                                         value, or change of stock to no par value, consolidation, merger, conveyance or otherwise)
                                         or to receive notice of meetings, or to receive dividends or subscription rights or otherwise
                                         until the Warrant shall have been exercised as provided herein. However, at the time
                                         of the exercise of this Warrant pursuant to Section 3 hereof, the Warrant Shares so purchased
                                         hereunder shall be deemed to be issued to such Holder as the record owner of such shares
                                         as of the close of business on the date on which this Warrant shall have been exercised.
	 	 	 
		8.	Assignment
                                         and Transfer of Warrant. This Warrant may not be assigned or transfer without
                                         the written consent with the Company.
	 	 	 
		9.	Loss,
                                         Theft, Destruction or Mutilation of Warrant; Exchange. The Company represents,
                                         warrants and covenants that (a) upon receipt by the Company of evidence and/or indemnity
                                         reasonably satisfactory to it of the loss, theft, destruction or mutilation of any Warrant
                                         or stock certificate representing the Warrant Shares, and in case of loss, theft or destruction,
                                         of indemnity reasonably satisfactory to it, and (b) upon surrender and cancellation of
                                         such Warrant or stock certificate, if mutilated, the Company will make and deliver a
                                         new Warrant or stock certificate of like tenor and dated as of such cancellation, in
                                         lieu of this Warrant or stock certificate, without any charge therefor. This Warrant
                                         is exchangeable at any time for an equal aggregate number of Warrants of different denominations,
                                         as requested by the holder surrendering the same, or in such denominations as may be
                                         requested by the Holder following determination of the Exercise Price. No service charge
                                         will be made for such registration or transfer, exchange or reissuance.



 


	 	10.	Saturdays, Sundays, Holidays, etc. If the last or appointed
day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or a legal
holiday, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday.



 






    	 	A-27	 



     


    

 



	 	11.	Effect of Certain Events. If at any time while this Warrant
or any portion thereof is outstanding and unexpired there shall be a transaction (by merger or otherwise) in which more than 50%
of the voting power of the Company is disposed of (collectively, a “Sale or Merger Transaction”), the Holder
of this Warrant shall have the right thereafter to purchase, by exercise of this Warrant and payment of the aggregate Exercise
Price in effect immediately prior to such action, the kind and amount of shares and other securities and property which it would
have owned or have been entitled to receive after the happening of such transaction had this Warrant been exercised immediately
prior thereto, subject to further adjustment as provided in Section 12.
	 	 	 




	 	12.	Adjustments of Exercise Price and Number of Warrant Shares.
The number of and kind of securities purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment
from time to time as set forth in this Section 12.
	 	 	 




		a.	Subdivisions,
                                         Combinations, Stock Dividends and other Issuances. If the Company shall, at any
                                         time while this Warrant is outstanding, (i) pay a stock dividend or otherwise make a
                                         distribution or distributions on any equity securities (including instruments or securities
                                         convertible into or exchangeable for such equity securities) in shares of Common Stock,
                                         (ii) subdivide outstanding shares of Common Stock into a larger number of shares, or
                                         (iii) combine outstanding Common Stock into a smaller number of shares, then the Exercise
                                         Price shall be multiplied by a fraction, the numerator of which shall be the number of
                                         shares of Common Stock outstanding before such event and the denominator of which shall
                                         be the number of shares of Common Stock outstanding after such event. Any adjustment
                                         made pursuant to this Section 12(a) shall become effective immediately after the record
                                         date for the determination of stockholders entitled to receive such dividend or distribution
                                         and shall become effective immediately after the effective date in the case of a subdivision
                                         or combination. The number of shares which may be purchased hereunder shall be increased
                                         proportionately to any reduction in Exercise Price, or decreased proportionately to any
                                         increase in Exercise Price, pursuant to this paragraph 12(a), so that after such adjustments
                                         the aggregate Exercise Price payable hereunder for the applicable number of shares shall
                                         be the same as the aggregate Exercise Price in effect just prior to such adjustments.



 


		b.	Other
                                         Distributions. If at any time after the date hereof the Company distributes to
                                         holders of its Common Stock, other than as part of its dissolution, liquidation or the
                                         winding up of its affairs, any shares of its capital stock, any evidence of indebtedness
                                         or any of its assets (other than Common Stock), then the number of Warrant Shares for
                                         which this Warrant is exercisable shall be increased to equal: (i) the number of Warrant
                                         Shares for which this Warrant is exercisable immediately prior to such event, (ii) multiplied
                                         by a fraction, (A) the numerator of which shall be the Fair Market Value (as defined
                                         below) per share of Common Stock on the record date for the dividend or distribution,
                                         and (B) the denominator of which shall be the Fair Market Value price per share of Common
                                         Stock on the record date for the dividend or distribution minus the amount allocable
                                         to one share of Common Stock of the value (as jointly determined in good faith by the
                                         Board of Directors of the Company and the Holder) of any and all such evidences of indebtedness,
                                         shares of capital stock, other securities or property, so distributed. For purposes of
                                         this Warrant, “Fair Market Value” shall equal the average closing
                                         trading price of the Common Stock on the Principal Market for the five (5) Trading Days
                                         preceding the date of determination or, if the Common Stock is not listed or admitted
                                         to trading on any Principal Market, and the average price cannot be determined as contemplated
                                         above, the Fair Market Value of the Common Stock shall be as reasonably determined in
                                         good faith by the Company’s Board of Directors and the Holder. If the Fair Market
                                         Value of the Common Stock cannot be determined by the Company’s Board of Directors
                                         and the Holder after five (5) business days, such determination shall be made by a third
                                         party appraisal firm mutually agreeable by the Board of Directors and the Holder, at
                                         the expense of the Company (the “Independent Appraiser”). The fair
                                         market value as determined by the Independent Appraiser shall be final. The Exercise
                                         Price shall be reduced to equal: (i) the Exercise Price in effect immediately before
                                         the occurrence of any event (ii) multiplied by a fraction, (A) the numerator of which
                                         is the number of Warrant Shares for which this Warrant is exercisable immediately before
                                         the adjustment, and (B) the denominator of which is the number of Warrant Shares for
                                         which this Warrant is exercisable immediately after the adjustment.



 






    	 	A-28	 



     


    

 


		c.	Merger,
                                         etc. If at any time after the date hereof there shall be a merger or consolidation
                                         of the Company with or into or a transfer of all or substantially all of the assets of
                                         the Company to another entity, then the Holder shall be entitled to receive upon or after
                                         such transfer, merger or consolidation becoming effective, and upon payment of the Exercise
                                         Price then in effect, the number of shares or other securities or property of the Company
                                         or of the successor corporation resulting from such merger or consolidation, which would
                                         have been received by the Holder for the shares of stock subject to this Warrant had
                                         this Warrant been exercised just prior to such transfer, merger or consolidation becoming
                                         effective or to the applicable record date thereof, as the case may be. The Company will
                                         not merge or consolidate with or into any other corporation, or sell or otherwise transfer
                                         its property, assets and business substantially as an entirety to another corporation,
                                         unless the corporation resulting from such merger or consolidation (if not the Company),
                                         or such transferee corporation, as the case may be, shall expressly assume in writing
                                         the due and punctual performance and observance of each and every covenant and condition
                                         of this Warrant to be performed and observed by the Company.
	 	 	 



		d.	Reclassification,
                                         etc. If at any time after the date hereof there shall be a reorganization or
                                         reclassification of the securities as to which purchase rights under this Warrant exist
                                         into the same or a different number of securities of any other class or classes, then
                                         the Holder shall thereafter be entitled to receive upon exercise of this Warrant, during
                                         the period specified herein and upon payment of the Exercise Price then in effect, the
                                         number of shares or other securities or property resulting from such reorganization or
                                         reclassification, which would have been received by the Holder for the shares of stock
                                         subject to this Warrant had this Warrant at such time been exercised.



 






    	 	A-29	 



     


    

 


	 	13.	Notice of Adjustment. Whenever the number of Warrant Shares
or number or kind of securities or other property purchasable upon the exercise of this Warrant or the Exercise Price is adjusted,
the Company, at its expense, shall promptly mail to the Holder of this Warrant a notice setting forth the number of Warrant Shares
(and other securities or property) purchasable upon the exercise of this Warrant and the Exercise Price of such Warrant Shares
after such adjustment and setting forth the computation of such adjustment and a brief statement of the facts requiring such adjustment.
	 	 	 




	 	14.	Authorized Shares. The Company covenants that during the
period the Warrant is outstanding and exercisable, it will reserve and keep available from its authorized and unissued Common
Stock a sufficient number of shares to provide solely for the issuance of the Warrant Shares upon the exercise of any and all
purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law, regulation, or rule of any applicable market or exchange.
	 	 	 




	 	15.	Compliance with Securities Laws. The Holder hereof acknowledges
that the Warrant Shares acquired upon the exercise of this Warrant, if not registered (or if no exemption from registration exists),
will have restrictions upon resale imposed by state and federal securities laws. Each certificate representing the Warrant Shares
issued to the Holder upon exercise (if not registered, for resale or otherwise, or if no exemption from registration exists) will
bear substantially the following legend: THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, TRANSFERRED, SOLD OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS.



 



	 	16.	Purpose of Warrant Shares. Without limiting the Purchaser’s
right to transfer, assign or otherwise convey the Warrant or Warrant Shares in compliance with all applicable securities laws,
the Holder of this Warrant, by acceptance hereof, acknowledges that this Warrant and the Warrant Shares to be issued upon exercise
hereof are being acquired solely for the Purchaser’s own account and not as a nominee for any other party, and that the
Purchaser will not offer, sell or otherwise dispose of this Warrant or any Warrant Shares to be issued upon exercise hereof except
under circumstances that will not result in a violation of applicable federal and state securities laws.



 






    	 	A-30	 



     


    

 



	 	17.	Miscellaneous.



 



		a.	Issue
                                         Date; Choice of Law; Venue; Jurisdiction. The provisions of this Warrant shall
                                         be construed and shall be given effect in all respects as if it had been issued and delivered
                                         by the Company on the date hereof. This Warrant shall be binding upon any successors
                                         or assigns of the Company. This Warrant will be construed and enforced in accordance
                                         with and governed by the laws of the State of New York, except for matters arising under
                                         the Act, without reference to principles of conflicts of law. Each of the parties consents
                                         to the exclusive jurisdiction of the Federal and State Courts sitting in the County of
                                         New York in the State of New York in connection with any dispute arising under this Warrant
                                         and hereby waives, to the maximum extent permitted by law, any objection, including any
                                         objection based on forumnonconveniens or venue, to the bringing of any such proceeding
                                         in such jurisdiction.



 


		b.	Modification
                                         and Waiver. This Warrant and any provisions hereof may be changed, waived, discharged
                                         or terminated only by an instrument in writing signed by the party against which enforcement
                                         of the same is sought. Any amendment effected in accordance with this paragraph shall
                                         be binding upon the Purchaser, each future holder of this Warrant and the Company. No
                                         waivers of, or exceptions to, any term, condition or provision of this Warrant, in any
                                         one or more instances, shall be deemed to be, or construed as, a further or continuing
                                         waiver of any such term, condition or provision.



 


		c.	Notices.
                                         Any notice or other communication required or permitted to be given hereunder shall
                                         be in writing by facsimile, mail or personal delivery and shall be effective upon actual
                                         receipt of such notice. The addresses for such communications shall be to the addresses
                                         as shown on the books of the Company or to the Company at the address set forth for Moxian
                                         China, Inc. in the Offering Documents. A party may from time to time change the address
                                         to which notices to it are to be delivered or mailed hereunder by notice in accordance
                                         with the provisions of this Section 19(c).



 


		d.	Severability.
                                         Whenever possible, each provision of this Warrant shall be interpreted in such manner
                                         as to be effective and valid under applicable law, but if any provision of this Warrant
                                         is held to be invalid, illegal or unenforceable in any respect under any applicable law
                                         or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not
                                         affect the validity, legality or enforceability of any other provision of this Warrant
                                         in such jurisdiction or affect the validity, legality or enforceability of any provision
                                         in any other jurisdiction, but this Warrant shall be reformed, construed and enforced
                                         in such jurisdiction as if such invalid, illegal or unenforceable provision had never
                                         been contained herein.



 


		e.	Specific
                                         Enforcement. The Company and the Holder acknowledge and agree that irreparable
                                         damage would occur in the event that any of the provisions of this Warrant were not performed
                                         in accordance with their specific terms or were otherwise breached. It is accordingly
                                         agreed that the parties shall be entitled to an injunction or injunctions to prevent
                                         or cure breaches of the provisions of this Warrant and to enforce specifically the terms
                                         and provisions hereof, this being in addition to any other remedy to which either of
                                         them may be entitled by law or equity.



 






    	 	A-31	 



     


    

 


		f.	Counterparts/Execution.
                                         This Warrant may be executed by facsimile and in any number of counterparts, and
                                         each such counterpart hereof shall be deemed to be an original instrument, but all such
                                         counterparts together shall constitute one agreement. Execution and delivery of this
                                         Warrant by facsimile transmission (including delivery of documents in Adobe PDF format)
                                         shall constitute execution and delivery of this Warrant for all purposes, with the same
                                         force and effect as execution and delivery of an original manually signed copy hereof.



 


[SIGNATURE
PAGE TO FOLLOW]


 






    	 	A-32	 



     


    

 









IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officers thereunto duly authorized.


 


Dated: April __, 2015


 


	MOXIAN
    CHINA, INC.	 
	 	 
	By:	 	 
	Name:	James
    Mengdong Tan	 
	Title:	Interim
    Chief Executive Officer	 








 






    	 	A-33	 



     


    

 


NOTICE
OF EXERCISE


 


To:       MOXIAN
CHINA, INC.


 


(1)        The
undersigned hereby elects to exercise the attached Warrant for and to purchase thereunder, ________________ shares of Common Stock,
and herewith makes payment therefor of $______________.


 


(2)        Please
issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name
as is specified below:


 


	 	 	 
	 	(Name)	 
	 	 	 
	 	 	 
	 	(Address)	 
	 	 	 
	 	 	 


 


(3)        Please
issue a new Warrant for the unexercised portion of the attached Warrant in the name of the undersignedas is specified below:


 


	 	 	BEIJING
    XINHUA HUIFENG EQUITY INVESTMENT CENTRE (LIMITED PARTNERSHIP)
	 	 	 
	 	 	(Name)
	 	 	 
	____________________	 	 
	(Date)	 	(Signature)
	 	 	 
	 	 	 
	 	 	(Address)
	 	 	 
	Dated:	 	 
	 	 	 
	 	 	 
	Signature	 	 


 






    	 	A-34	 



     


    

 


ASSIGNMENT
FORM


 


(To
assign the foregoing warrant, execute


this
form and supply required information.


Do
not use this form to exercise the warrant.)


  


FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to


 


_________________________________________________
whose address is


 


_______________________________________________________________.


 


_______________________________________________________________


 


                                                                        Dated:
______________,


 


 


                                          Holder’s
Signature:    _____________________________


 


                                          Holder’s
Address:      _____________________________


 


                                                                             _____________________________


 


Signature
Guaranteed: ___________________________________________


  


NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.


 


 



    	 	A-35	 



     


    

 


Exhibit
B


 


Amendment
Agreement


 


 



     

     


    

   


AMENDMENT AGREEMENT


 


THIS AMENDMENT AGREEMENT
(this “Agreement”) is made as of the 13th of August, 2015 by and between Moxian, Inc., a Nevada corporation (the “Company”),
and Beijing Xinhua Huifeng Equity Investment Centre, a limited partnership formed under the laws of People’s Republic of
China (the “Xinhua”). Each of the capitalized terms not otherwise defined herein shall have the meanings ascribed to
them in the Xinhua Subscription Agreement dated June 4, 2015 as defined below.


 


RECITALS:


 


WHEREAS, the Company
entered into a subscription agreement (“Zhongtou Subscription Agreement”) with Zhongtou Huifeng Investment Management
(Beijing) Co. Ltd. (“Zhongtou”) on April 24, 2015, whereby the Company agreed to sell an aggregate of 8,169,000 shares
of the Company’s common stock par value $.001 per share (“Common Stock”) at a per share price of $1.00 for gross
proceeds of $8,190,000 (approximately RMB50,000,000)(the “Purchase Price”) and to issue to Zhongtou for no additional
consideration a warrant (the “Warrant”) to purchase in the aggregate of 32,000,000 shares (“Warrant Shares”)
of Common Stock at an exercise price of $2.00 per share, exercisable on or prior to July 31, 2015. On June 4, 2015, the Company
and Zhongtou entered into a Termination Agreement to terminate the Zhongtou Subscription Agreement as Zhongtou’s principals
have determined to make the investment described in the Zhongtou Subscription Agreement through a different entity, Xinhua. Also
on June 4, 2015, the Company and Xinhua entered into a new Subscription Agreement (“Xinhua Subscription Agreement”)
on substantially the same terms as the Zhongtou Subscription Agreement (the “Transaction”), substantially in the form
of Exhibit A attached hereto. Pursuant to the Xinhua Subscription Agreement, Xinhua shall remit the Purchase Price of $8,190,000
to the Company on or before May 31, 2015 (the “Closing Date”) and the Warrant shall be exercised by Xinhua on or before
July 31, 2015 (the “Expiration Date”);


 


WHEREAS, the parties
hereto desire to amend the Xinhua Subscription Agreement as set forth herein;


 


NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as
follows:


 


Section 1.                   Amendment of the Xinhua
Agreement.


 


		(a)	The Closing Date of the Transaction shall be extended to September 30, 2015.



 


		(b)	The Expiration Date of the Warrant shall be extended to September 30, 2015.



  


 



    	 	B-1	 



     


    

 


Section 2.                   Miscellaneous.


 


(a)               
Expenses. Each party shall bear its own costs and expenses, including legal fees, incurred or sustained in connection
with the preparation of this Agreement and related matters.


(b)              
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and Xinhua.


(c)               
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be delivered as set forth in the Xinhua Subscription Agreement.


(d)              
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties


(e)               
Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.


(f)               
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be determined in accordance with the provisions of the Xinhua Subscription Agreement.


(g)              
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.


(h)              
Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and
shall not be deemed to limit or affect any of the provisions hereof.


(i)                
Except as specifically contemplated by this Agreement, the Xinhua Subscription Agreement shall remain in full force and
effect, unaffected by this Agreement. 



    	 	B-2	 



     


    

 


IN WITNESS WHEREOF, the parties have caused
        this Agreement to be executed as of the date first written above.


 





	 	Moxian, Inc.
	 	 	 
	 	By:	
	 	Name:	James Mengdong Chen
	 	Title: 	CEO
	 	 	 
	 	Beijing Xinhua Huifeng
        Equity Investment Centre
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title: 	 



  


 


B-3